Pacira BioSciences (FRA:82P) ROCE %: 2.93% (As of Mar. 2026)

What is Pacira BioSciences ROCE %?

Pacira BioSciences FRA:82P +6.74% 74 ROCE % is 2.93% as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 74/100 and a GF Value™ of €24.22. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pacira BioSciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 2.93%.

Pacira BioSciences (FRA:82P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pacira BioSciences ROCE % Related Terms

Pacira BioSciences ROCE % Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences ROCE % Chart

Pacira BioSciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

6.82

3.27

5.17

-3.73

2.48

Pacira BioSciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															3.89	0.59	4.33	1.35	2.93

74GF Score

Pacira BioSciences Inc FRA:82P

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Pacira BioSciences ROCE % Calculation

Pacira BioSciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	26.884	/	( ( (1483.608 - 295.974)	+	(1080.239 - 102.984) )	/ 2 )
	=	26.884	/	( (1187.634	+	977.255)	/ 2 )
	=	26.884	/	1082.4445
	=	2.48 %

Pacira BioSciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	28.288	/	( ( (1080.239 - 102.984)	+	(1045.382 - 94.101) )	/ 2 )
	=	28.288	/	( ( 977.255	+	951.281 )	/ 2 )
	=	28.288	/	964.268
	=	2.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 2.93% mean?

Pacira BioSciences (FRA:82P) has a ROCE % of 2.93% as of Mar. 2026.

Is Pacira BioSciences' ROCE % too high?

Pacira BioSciences' current ROCE % is 2.93%. The Drug Manufacturers industry median ROCE % is 7.00. Pacira BioSciences' value of 2.93% is 58.1% below this industry median. Overall, Pacira BioSciences has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.

How does Pacira BioSciences' ROCE % compare to ETON and AMPH?

Pacira BioSciences' ROCE % of 2.93% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Pacira BioSciences' value of 2.93% is 58.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current ROCE % of 2.93% is 58.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current ROCE % is 2.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Pacira BioSciences stock overvalued right now?

Pacira BioSciences (FRA:82P) has a current ROCE % of 2.93%. The stock's GF Value™ is €24.22, compared to a current price of €20.60 — trading 14.9% below its estimated fair value. The current ROCE % is 2.93% and 58.1% below the Drug Manufacturers industry median of 7.00. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current ROCE % is 2.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €20.60 is trading 14.9% below its estimated GF Value™ of €24.22.

Key valuation signals for FRA:82P:

ROCE %: 2.93%
GF Value™: €24.22 vs. price of €20.60 (14.9% below fair value)
GF Score™: 74/100 with 6 warning signs
Industry Position: 58.1% below the Drug Manufacturers median

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ETON AMPH ESPR ALVO BIOA XERS COLL TLRY IRWD PAHC XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges PCRX:USA 82P:Germany

Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005

Website https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

74GF Score

Get the complete analysis for FRA:82P

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.60

Price

€24.22

GF Value

View FRA:82P Analysis

See ROCE % data for all stocks →